IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
This marks the first time that a hyaluronic acid dermal filler has received FDA approval for temple hollowing. Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm ...
The US Food and Drug Administration (FDA) has approved Juvéderm Voluma XC (Allergan) to correct age-related volume deficits in the midface in adults aged 21 years and older, the company announced ...
Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback